SODIUM ACETATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for sodium acetate and what is the scope of freedom to operate?
Sodium acetate
is the generic ingredient in one branded drug marketed by Amneal, Extrovis, Fresenius Kabi Usa, Hikma, Hospira, Milla Pharms, and Somerset Theraps Llc, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for sodium acetate. Six suppliers are listed for this compound.
Summary for SODIUM ACETATE
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 7 |
| NDAs: | 7 |
| Drug Master File Entries: | 9 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 230 |
| Drug Prices: | Drug price trends for SODIUM ACETATE |
| What excipients (inactive ingredients) are in SODIUM ACETATE? | SODIUM ACETATE excipients list |
| DailyMed Link: | SODIUM ACETATE at DailyMed |
Pharmacology for SODIUM ACETATE
| Drug Class | Osmotic Laxative |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM ACETATE
US Patents and Regulatory Information for SODIUM ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 206687-001 | Oct 30, 2017 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Somerset Theraps Llc | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 219826-001 | Sep 18, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Milla Pharms | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 214805-004 | Jan 22, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Milla Pharms | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 214805-001 | May 4, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch